In plain words
One trial found less weight regain with pasteurized Akkermansia than placebo, and another found a smaller drop that missed statistical significance. A third said an enriched dairy product may help weight management. In a fourth, weight fell in both groups alike, except among people starting with little Akkermansia in the gut.
The short answer
Three of the four randomized trials on this page lean toward lower weight or less regain; the ledger has no doses. A 24-week trial in 90 adults found 1.2 kg regained on pasteurized Akkermansia versus 3.2 kg on placebo (2026). A 3-month trial (2019; no n in the ledger) found a 2.27 kg larger drop that missed significance. An 8-week trial in 66 adults concluded a dairy product may help weight management (2025). A 12-week trial in 58 people with type 2 diabetes found no group difference, except among those starting with little Akkermansia (2025). Certainty is low: each small trial tested a different product, and none was repeated.
Where the evidence sits
Lower weight or less regain
No difference between groups
■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data
Who says what
| Source | Finding | Design | People | Dose and length | Funding and independence |
|---|---|---|---|---|---|
| Mount et al., 2026 | Less regain: 1.2 vs 3.2 kg | Randomized, placebo-controlled | 90 | Not in ledger; 24 weeks | Not in ledger |
| Depommier et al., 2019 | 2.27 kg lower, not significant | Randomized, placebo-controlled | Not in ledger | Not in ledger; 3 months | Not in ledger |
| Aalipanah et al., 2025 | May help weight management | Randomized trial | 66 | Not in ledger; 8 weeks | Not in ledger |
| Zhang et al., 2025 | No group difference; drop if starting levels low | Randomized, placebo-controlled | 58 | Not in ledger; 12 weeks | Not in ledger |
| Ruscio, 2024 | 5 lbs more lost, "pretty minimal" | Practitioner commentary describing a randomized trial | None | 3 months | Re-reads a trial, not new data |
| Roshanravan et al., 2021 | More trials needed | Review authors' conclusion | None | None | Not in ledger |
Less regain: 1.2 vs 3.2 kg
2.27 kg lower, not significant
May help weight management
No group difference; drop if starting levels low
5 lbs more lost, "pretty minimal"
More trials needed
Did it help people keep lost weight off?
Mount and colleagues (2026) randomized 90 adults with overweight or obesity who had lost weight on a diet to pasteurized Akkermansia or placebo for a 24-week maintenance period; the ledger has no dose for it.
Here we show that MucT led to lower body weight regain versus placebo at the end of the weight maintenance period (MucT: 1.2 ± 0.7 kg, placebo: 3.2 ± 0.4 kg, P = 0.012).
What did the shorter trials find?
Depommier and colleagues (2019) gave overweight, insulin-resistant adults live or pasteurized Akkermansia for 3 months; the ledger has no n or dose for it.
Pasteurized A.muciniphila supplementation slightly decreased body weight (-2.27±0.92kg, P=0.091) as compared to the Placebo group
Michael Ruscio, DC (2024), describes a small 3-month trial that appears to be this one, reports 5 lbs more lost than on placebo, and calls that pretty minimal.
Aalipanah and colleagues (2025) tested a dairy product enriched with an Akkermansia postbiotic in 66 adults with overweight or obesity for 8 weeks; the ledger has no dose or weight figures for it. They concluded it may have favorable effects on weight management.
Did it matter who took it?
Zhang and colleagues (2025) gave the AKK-WST01 strain or placebo to 58 people with type 2 diabetes and overweight or obesity for 12 weeks; the ledger has no dose for it.
Both groups showed decreases in body weight and glycated hemoglobin (HbA1c), without significant between-group differences.
In people starting with little Akkermansia in the gut, the authors report significant drops in weight and fat mass not seen on placebo. In people starting with a lot, the strain settled poorly and brought no significant clinical improvement.
Why the sources disagree
No two measurements in the ledger contradict each other outright. The trials differ in people (after diet-led weight loss, adults with overweight, type 2 diabetes), in product (a pasteurized strain, a dairy postbiotic, AKK-WST01) and in measure (regain against weight change), over 8 to 24 weeks. The commentary differs in tone: Ruscio (2024) calls the 3-month trial's gap pretty minimal, and Roshanravan and colleagues (2021) wrote that future clinical trials are needed to verify the benefits for obesity.
What would settle it
A placebo-controlled randomized trial of one defined Akkermansia product at a stated daily dose for at least 24 weeks in adults with overweight, with weight change as the pre-registered main outcome, analyzed by starting gut Akkermansia level. A matching result from a second, independent research group would move certainty toward moderate.
How this page was made
The 6 sources are four randomized trials, a 2021 review and a practitioner web page, found through a literature search. Animal studies, and trials that gave other supplements and measured Akkermansia as an outcome, were left out. Every claim was copied word for word into the Longevity Circle ledger and checked against the original text, and the Longevity Circle evidence editor approved each one. Certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.
Changelog: 29 Sep 2026, first version, 6 sources.
